Executive roles reshuffled at Pacific Biosciences (NASDAQ: PACB)

Rhea-AI Filing Summary

Pacific Biosciences of California, Inc. reported an internal, interim reassignment of executive responsibilities. Effective January 28, 2026, Chief Operating Officer Mark Van Oene now oversees the company’s sales and customer support teams, duties that were previously handled by President and Chief Executive Officer Christian Henry.

At the same time, Mr. Henry has temporarily taken over responsibility for operations and research and development, which had been under Mr. Van Oene. Both executives keep their existing roles and core duties, and the company states there will be no changes to their titles or compensation in connection with this shift.

0001299130false00012991302026-01-282026-01-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

January 28, 2026

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-34899			16-1590339
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

1305 O’Brien Drive

Menlo Park, California 94025

(Address of principal executive offices) (Zip Code)

(650) 521-8000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

PACB

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

On February 3, 2026, Pacific Biosciences of California, Inc. (the “Company”) announced that, effective January 28, 2026, Mark Van Oene, the Company’s Chief Operating Officer, will on an interim basis assume responsibilities for the Company’s sales and customer support organizations, which were previously assigned to Christian Henry, the Company’s President & Chief Executive Officer. Mr. Henry will on an interim basis assume responsibilities for the Company’s operations and research and development organizations, which were previously assigned to Mr. Van Oene. Both Mr. Henry and Mr. Van Oene will retain their other core responsibilities, and there will be no change to the title or compensation of Mr. Henry or Mr. Van Oene as a result of the foregoing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Pacific Biosciences of California, Inc.
			By:			/s/ Brett Atkins
						Brett Atkins
						General Counsel
Date: February 3, 2026

FAQ

What executive changes did Pacific Biosciences (PACB) disclose in this 8-K?

Pacific Biosciences disclosed an interim reshuffling of executive duties. Chief Operating Officer Mark Van Oene now oversees sales and customer support, while President and CEO Christian Henry has assumed responsibility for operations and research and development, effective January 28, 2026.

Did any executives leave Pacific Biosciences (PACB) in this leadership update?

No executives left Pacific Biosciences in this update. The filing describes only an interim reassignment of responsibilities between CEO Christian Henry and COO Mark Van Oene, with both remaining in their existing positions and continuing to hold their core responsibilities.

How did responsibilities shift between the CEO and COO at Pacific Biosciences (PACB)?

COO Mark Van Oene now manages sales and customer support, duties previously handled by CEO Christian Henry. In turn, Henry has taken over operations and research and development from Van Oene. These changes are described as interim reallocations of responsibilities within the existing leadership team.

Are there any changes to executive pay in Pacific Biosciences (PACB) following this 8-K?

The filing states there will be no change to the title or compensation of either CEO Christian Henry or COO Mark Van Oene as a result of the interim reassignment of responsibilities. Their pay and formal positions remain the same despite the internal shift in duties.

When did the leadership responsibility changes at Pacific Biosciences (PACB) take effect?

The leadership responsibility changes took effect on January 28, 2026. The company reported that date as the effective time when COO Mark Van Oene assumed sales and customer support and CEO Christian Henry assumed operations and research and development responsibilities on an interim basis.

Does the Pacific Biosciences (PACB) 8-K mention new executive titles?

The 8-K explicitly notes that there will be no change to the title of either executive. Christian Henry remains President and Chief Executive Officer, and Mark Van Oene remains Chief Operating Officer, even as they temporarily swap certain organizational responsibilities.